|
| Variants of concern |
| Alpha | Beta | Gamma | Delta | Omicron |
|
| Pango lineages | B.1.1.7 | B.1.351
B.1.351.2
B.1.351.3 | P.1
P.1.1
P.1.2 | B.1.617.2
AY.1
AY.2
AY.3 | B.1.1.529
BA.1
BA.2
BA.4
BA.5 |
|
| Epidemiology | Date and place of initial detection | September 2020, UK | May 2020, South Africa | November 2020, Brazil | October 2020, India | November 2021, Botswana |
| Date of designation | December 2020 | December 2020 | January 2021 | VOI: April 2021
VOC: May 2021 | VOC: November 2021 |
| Global spread | 48% | 7% | 7% | 14% | 43% |
| Geographic localization | Worldwide | South Africa | South America | Asia | Worldwide |
|
| Predominant mutations | N501Y
D614G, P681H | K417N, E484K, N501Y
D614G | K417T, E484K, N501Y
D614G | L452R, E484Q, T478K
D614G, P681H | N501, H69-, Y453F, L18, K417, P681, E484, Q677, S477, Y144-, H655, S3675 |
|
| Phenotypic impacts | Transmissibility | (i) High transmissibility
(ii) High rate of secondary attack | (i) High transmissibility | (i) High transmissibility | (i) High transmissibility
(ii) High rate of secondary attack
(iii) High transmissibility between vaccinated and unvaccinated individuals | (i) High transmissibility |
| Disease severity | (i) Increased risk of hospitalization
(ii) Increased risk of severity
(iii) Increased risk of mortality | (i) Increased risk of in-hospital mortality | (i) Possible increased risk of hospitalization | (i) Increased risk of hospitalization | (i) Possible risk of hospitalization |
| Risk of reinfection | (i) Neutralizing activity retained
(ii) Risk of reinfection remains similar | (i) Reduction in neutralizing activity reported
(ii) T cell response remains effective | (i) Moderate reduction in neutralizing activity reported | (i) Reduction in neutralizing activity reported | (i) Reduction in neutralizing activity reported |
| Diagnosis | (i) Limited impact—S gene target failure
(ii) No impact on overall result from multiple target RT-PCR
(iii) No impact on AgRDTs observed | (i) No impact on RT-PCR or AgRDTs observed | (i) None reported to date | (i) None reported to date | (i) S-assay within TaqPath tests gives negative results
(ii) No impact on result from multiple target RT-PCR |
|
